A sustainable agricultural solution that uses cellulolytic nitrogen-fixing bacteria combined with composted sunflower stem and leaf residues to enhance soil physicochemical and biological properties. The approach eliminates chemical pre-treatments, recycles agricultural waste, and offers an environmentally friendly fertilizer alternative.
This research proposes a sustainable soil enhancement approach that leverages cellulolytic nitrogen-fixing bacteria combined with composted lignocellulosic sunflower stem and leaf residues. The core value proposition is improving soil physicochemical and biological properties through natural enzymatic reactions, eliminating the need for chemical pre-treatments, and converting agricultural waste into a productive resource. By recycling herbal wastes as a substitute for synthetic inputs, the solution supports environmentally responsible farming while reducing pollution associated with conventional soil treatment methods.
Key features:
The research is currently at an early-to-mid stage of development. The team has established expertise in antimicrobial, antivirulence, and antibiofilm properties of plant-derived compounds, along with experience in abiotic stress tolerance mechanisms in plants. Future validation will involve inoculating composted sunflower residues with relevant bacteria species and applying the mixture as fertilizer from germination through maturity. Comprehensive soil and plant analyses will be conducted to validate efficacy, with performance measured by improvements in soil properties and crop yield outcomes.
Marmara University is a comprehensive public university in Istanbul, serving a large academic community across multiple urban campuses. Industry engagement is structured through dedicated liaison and technology transfer functions that broker sponsored research, IP, and startup formation, with shared laboratories and specialized instrumentation accessible to partners. Clinical translation is enabled by integration with an affiliated training and research hospital, offering access to diverse patient populations and regulated environments for trials and validation. Research is supported by TÜBİTAK and other national agencies, alongside competitive international programs and industry-sponsored projects. A centralized IP and contracting office streamlines agreements and corporate placements to shorten time from first contact to execution.